Skip to main content
OpenTrials

Clinical trial condition

Lentivirus Infections

Explore clinical trials studying Lentivirus Infections. Study availability and eligibility vary by location and protocol.

5,647 public trials 305 recruiting studies
Refine in advanced search Browse all conditions

Lentivirus Infections trial results

Completed

Safety of and Immune Response to an HIV Preventive Vaccine (HIV-1 Gag DNA Alone or With IL-15 DNA) Given With or Without 2 Different Booster Vaccinations in HIV Uninfected Adults

NCT00115960

Conditions
Blood-Borne Infections, Communicable Diseases, Genital Diseases, +11 more
Locations
  • Brigham and Women's Hosp. CRS Boston, Massachusetts, United States
  • NY Blood Ctr./Union Square CRS New York, United States
  • HIV Prevention & Treatment CRS New York, United States
  • Univ. of Rochester HVTN CRS Rochester, New York, United States
View Trial Details
Completed

Safety of and Immune Response to a DNA HIV Vaccine Followed by an Adenoviral Vaccine Boost Given Three Different Ways to HIV Uninfected Adults

NCT00384787

Conditions
Blood-Borne Infections, Communicable Diseases, Genital Diseases, +11 more
Locations
  • Alabama Vaccine CRS Birmingham, Alabama, United States
  • Brigham and Women's Hospital Vaccine CRS (BWH VCRS) Boston, Massachusetts, United States
  • NY Blood Ctr./Union Square CRS New York, United States
  • Columbia P&S CRS New York, United States
View Trial Details
Completed

Safety and Immune Response Study of High-Dose Canarypox ALVAC-HIV Vaccine in Healthy, HIV Uninfected Adults

NCT00027261

Conditions
Blood-Borne Infections, Communicable Diseases, Genital Diseases, +12 more
Locations
  • Alabama Vaccine CRS Birmingham, Alabama, United States
  • San Francisco Vaccine and Prevention CRS San Francisco, California, United States
  • UCSF, Gen. Clinical Research Ctr., Mt. Zion Hosp. San Francisco, California, United States
  • Project Brave HIV Vaccine CRS Baltimore, Maryland, United States
View all 13 locations
View Trial Details
Completed

Safety of and Immune Response to an HIV-1 DNA Vaccine (VRC HIVDNA009-00-VP) in HIV Uninfected Adults

NCT00071851

Conditions
Blood-Borne Infections, Communicable Diseases, Genital Diseases, +11 more
Locations
  • Alabama Vaccine CRS Birmingham, Alabama, United States
  • San Francisco Vaccine and Prevention CRS San Francisco, California, United States
  • Project Brave HIV Vaccine CRS Baltimore, Maryland, United States
  • Johns Hopkins Bloomberg School of Public Health,Ctr for Immunization Research,Project SAVE-Baltimore Baltimore, Maryland, United States
View all 14 locations
View Trial Details
Completed

Safety of and Immune Response to Two HIV Vaccine Formulations (rMVA-HIV and rFPV-HIV) Alone or in Combination in HIV Uninfected Adults

NCT00083603

Conditions
Blood-Borne Infections, Communicable Diseases, Genital Diseases, +11 more
Locations
  • Alabama Vaccine CRS Birmingham, Alabama, United States
  • Saint Louis Univ. School of Medicine, HVTU St Louis, Missouri, United States
  • Univ. of Rochester HVTN CRS Rochester, New York, United States
  • FHCRC/UW Vaccine CRS Seattle, Washington, United States
View Trial Details
Completed

Safety of and Immune Response to an HIV Vaccine (VRC-HIVDNA009-00-VP) Administered With Interleukin-2/Immunoglobulin (IL-2/Ig) DNA Adjuvant in Uninfected Adults

NCT00069030

Conditions
Blood-Borne Infections, Communicable Diseases, Genital Diseases, +11 more
Locations
  • Project Brave HIV Vaccine CRS Baltimore, Maryland, United States
  • Brigham and Women's Hosp. CRS Boston, Massachusetts, United States
  • Fenway Community Health Clinical Research Site (FCHCRS) Boston, Massachusetts, United States
  • NY Blood Ctr./Union Square CRS New York, United States
View Trial Details
Completed

Safety of and Immune Response to an HIV-1 Vaccine Boost (VRC-HIVADV014-00-VP) in HIV Uninfected Adults Who Participated in HVTN 052

NCT00091416

Conditions
Blood-Borne Infections, Communicable Diseases, Genital Diseases, +11 more
Locations
  • Johns Hopkins Bloomberg School of Public Health,Ctr for Immunization Research,Project SAVE-Baltimore Baltimore, Maryland, United States
  • Fenway Community Health Clinical Research Site (FCHCRS) Boston, Massachusetts, United States
  • Saint Louis Univ. School of Medicine, HVTU St Louis, Missouri, United States
  • HIV Prevention & Treatment CRS New York, United States
View Trial Details
Completed

Safety of and Immune System Response to an HIV Vaccine (EP HIV-1090) in HIV Uninfected Adults

NCT00054860

Conditions
Blood-Borne Infections, Communicable Diseases, Genital Diseases, +11 more
Locations
  • Brigham and Women's Hosp. CRS Boston, Massachusetts, United States
  • Fenway Community Health Clinical Research Site (FCHCRS) Boston, Massachusetts, United States
  • Saint Louis Univ. School of Medicine, HVTU St Louis, Missouri, United States
  • Miriam Hospital's HVTU Providence, Rhode Island, United States
View Trial Details

Related conditions